-
.
- Ελληνικά
China[/B] today gave the green light for the use under certain conditions of the anti-COVID drug.19 from the US pharmaceutical group Pfizer, which is marketed under the brand name Paxlovid, the country's national drug agency said.
The decision comes as Beijing hosts the Winter Olympics and at a time when the country is experiencing some small sporadic outbreaks of the virus. However, Chinese authorities have not approved any foreign vaccines against COVID-19 so far.
Paxlovid was licensed in late December in the US and since then in about 40 countries. Pfizer has made sales of this drug that totaled $72 million in 2021 and hopes to produce 120 million doses throughout 2022.
The Chinese national medical products authority approved the use of this drug under certain conditions and, like other countries, only for patients at risk of developing a severe form of COVID-19, it says on its website.
Pfizer will continue studies on its drug and submit the results to the Chinese regulator, it clarifies in its statement.
Since the outbreak, China has been following a zero-tolerance strategy on COVID-19, which consists of making every effort to limit the occurrence of new cases, which generally amount to only a few dozen per day.
For example, the country's Ministry of Health today announced only 40 new domestic infections across the country.
Although these numbers are far too low compared to those recorded daily in other countries around the world, they prompt authorities to redouble vigilance at a time when Beijing is hosting the Winter Olympics until February 20.
Source: Proto Thema
Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times
Source
